SELLAS Life Sciences (SLS) Profit After Tax (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Profit After Tax of -$8.4 million for Q1 2026, down 44.5% year-over-year from -$15.1 million in Q1 2025, and down 9.16% quarter-over-quarter from -$7.7 million in Q4 2025.
SELLAS Life Sciences (SLS) Profit After Tax (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Profit After Tax for 17 consecutive years, with -$8.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 44.5% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at -$29.5 million (down 8.7% YoY), while the FY2025 annual figure was -$26.9 million, up 12.89% from the prior year.
- Profit After Tax slipped to -$8.4 million in Q1 2026 per SLS's latest filing, from -$7.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$5.8 million in Q1 2025 and bottomed at -$16.7 million in Q1 2022.
- Historically, Profit After Tax has averaged -$8.5 million across 5 years, with a median of -$8.1 million in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 596.8% — and 2025, when it surged 39.23%.
- SELLAS Life Sciences' Profit After Tax stood at -$9.1 million in 2022, then increased by 10.8% to -$8.1 million in 2023, then increased by 17.2% to -$6.7 million in 2024, then fell by 14.22% to -$7.7 million in 2025, then declined by 9.16% to -$8.4 million in 2026.
- Business Quant data shows SLS's Profit After Tax at -$8.4 million in Q1 2026, -$7.7 million in Q4 2025, and -$6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | -9.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.61 Mn |
| Mar 31, 2026 | -8.40 Mn |
| Dec 31, 2025 | -7.70 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | -7.47 Mn |
| Mar 31, 2024 | -9.57 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -9.27 Mn |
| Jun 30, 2023 | -8.84 Mn |
| Mar 31, 2023 | -11.10 Mn |
| Dec 31, 2022 | -9.12 Mn |
| Sep 30, 2022 | -7.02 Mn |
| Jun 30, 2022 | -8.41 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -6.60 Mn |
| Sep 30, 2021 | -7.09 Mn |